Who are Continue Ritonavir-boosted PI+Rosuvastatin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/continue-ritonavir-boosted-pi-rosuvastatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Continue Ritonavir-boosted PI+Rosuvastatin — Competitive Intelligence Brief

Continue Ritonavir-boosted PI+Rosuvastatin (Continue Ritonavir-boosted PI+Rosuvastatin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination (protease inhibitor + statin). Area: Infectious Disease / Cardiovascular.

marketed Antiretroviral combination (protease inhibitor + statin) HIV protease (PI component); HMG-CoA reductase (rosuvastatin component) Infectious Disease / Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Continue Ritonavir-boosted PI+Rosuvastatin (Continue Ritonavir-boosted PI+Rosuvastatin) — Juan A. Arnaiz. This combination uses ritonavir-boosted protease inhibitor antiretroviral therapy to suppress HIV replication, while rosuvastatin reduces cholesterol levels to manage cardiovascular risk in HIV-positive patients.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Continue Ritonavir-boosted PI+Rosuvastatin TARGET	Continue Ritonavir-boosted PI+Rosuvastatin	Juan A. Arnaiz	marketed	Antiretroviral combination (protease inhibitor + statin)	HIV protease (PI component); HMG-CoA reductase (rosuvastatin component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination (protease inhibitor + statin) class)

Juan A. Arnaiz · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Continue Ritonavir-boosted PI+Rosuvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/continue-ritonavir-boosted-pi-rosuvastatin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab